Join IPM at AIDS 2016!
Join IPM in Durban 18-22 July for the 21st International AIDS Conference (AIDS 2016) to get the latest research on IPM's monthly dapivirine ring, and hear IPM and our partners discuss how to advance promising prevention technologies for women.
Find us at the sessions below and visit us in the Global Village at booth 380 throughout the week for stimulating conversations and giveaways.
And follow us on Twitter at @IPMicrobicides to keep up with news, photos and quotes that catch our eye!
Mon., 18 July
Global Village Activities
Research Literacy Session: Dapivirine Ring Licensure Program
16:00-17:00, Global Village, Research Literacy Networking Zone, Booth 606
Speakers from IPM and clinical trial research partners will explain the next steps for IPM's ring following the Phase III results, including the regulatory pathway and timeline, open-label follow-on studies and the role of advocates and communities.
HIV Prevention for Pregnant & Breastfeeding Women: Long Overdue. But is it Time to Deliver?
14:45-16:45, Session Room 12
Organized by: Microbicide Trials Network with AVAC, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, IPM, Jhpiego and PEPFAR
This session will focus on meeting the HIV prevention needs of pregnant and breastfeeding women and the potential role of promising new technologies. Panelists include Zeda Rosenberg, CEO, IPM.
Tues., 19 July
Dapivirine Ring Oral Presentation
IPM partner oral presentation
Session: PrEP: New Drugs, New Questions
11:00-12:30, Session Room 11
TUAC0105LB. Residual Dapivirine Ring Levels Indicate Higher Adherence to Vaginal Ring is Associated with HIV-1 Protection
Wed., 20 July
Global Village Activities
The HIV Prevention Landscape for Women: A Look at New and Emerging HIV Prevention Options, Including PrEP, Vaginal Rings and New Products in Development
13:00-14:30, Global Village, Session Room 1
This interactive session helps participants understand the implications of existing products and those in development as prevention options, and discuss women’s needs and expectations for new interventions. Speakers include Annalene Nel, Chief Medical Officer, IPM.
Dapivirine Ring Posters
12:30-14:30, Poster Exhibition, First Level
IPM poster presentations
- WEPEC130. Engaging Men in Microbicide Vaginal Ring Trials: Successes and Challenges
- WEPEC220. A Preliminary Evaluation of the HIV Testing Algorithm in the IPM 027 Trial
- WEPEC268. Self-reported Ring Removals and Expulsions of the Dapivirine Vaginal Ring: Qualitative Data from The Ring Study (IPM 027)
- WEPEC269. The Management of HIV Discordant Results at Madibeng Centre for Research on a Phase III HIV Microbicide Clinical Trials
- WEPED304. Acceptability of the Dapivirine Vaginal Ring to Female Participants and Male Partners Involved in The Ring Study
IPM partner oral poster discussion
Session: Prevention for Women: The Need for Multidisciplinary Approaches
13:00-14:00, Session Room 8
WEPDC0203. HIV Pre-exposure Prophylaxis (PrEP) Formulation Preference Among Women Participating in the Qualitative Component of the ASPIRE (MTN-020) Study
IPM partner poster presentations
- WEPEB122. Expanding the Mix of Contraceptive Methods in an HIV Prevention Trial
- WEPEC265. Key Insights into Acceptability and Use of the Vaginal Ring: Results of the MTN-020 ASPIRE Trial Qualitative Component